---
schema_version: "secwatch.filing_event.v1"
accession: "0001077183-23-000099"
form_type: "8-K"
ticker: "NEO"
cik: "0001077183"
company_name: "NEOGENOMICS INC"
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T00:26:33.021157+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NeoGenomics Q2 revenue up 18% to $147M; net loss narrows 31% to $24M

## Summary
- Revenue of $147M (+18% YoY); Clinical Services $123M (+17%), Advanced Diagnostics $24M (+22%).
- Net loss decreased 31% to $24M; Adjusted EBITDA improved 87% to -$2M from -$16M.
- Adjusted Net Loss $7M vs $20M in prior year; cash and marketable securities $409M.
- FY 2023 guidance raised: revenue $565-575M, net loss $(107)-(100)M, Adjusted EBITDA $(13)-(10)M.
- Pharma Services segment rebranded as Advanced Diagnostics; restructuring charges included in Q2.

## SEC filing metadata
- accession: 0001077183-23-000099
- form_type: 8-K
- ticker: NEO
- cik: 0001077183
- company_name: NEOGENOMICS INC
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1077183/000107718323000099/0001077183-23-000099-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1077183/000107718323000099/neo-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001077183-23-000099
- JSON: https://secwatch.observer/filing/0001077183-23-000099.json
- Plain text: https://secwatch.observer/filing/0001077183-23-000099.txt

## Key facts
- Earnings Releases
  NEOGENOMICS INC reported second fiscal quarter of 2023 results: revenue $147 million, net income $24 million. Guidance raised.
  - Period: second fiscal quarter of 2023
  - Revenue: $147 million
  - Net income: $24 million
  - Guidance: raised
  - Result: reported results
  source text: as expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- NeoGenomics Reports Second Quarter 2023 Results Second Quarter Revenue Increased 18% to $147 Million Fort Myers, Florida (August 8, 2023) - NeoGenomics, Inc. (NASDAQ: NEO) (the “ Company ” ), a leading oncology testing services company, today announced its second-quarter results
  evidence_url: https://www.sec.gov/Archives/edgar/data/1077183/000107718323000099/0001077183-23-000099-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.